Mountain View, CA, United States of America

Heidi N Leblanc

This inventor holds 22 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Human Antibody Development. Top assignees: E. R. Squibb Sons, Inc., Pfizer Corporation, Bristol-Myers Squibb Compnay. Active years: 2011-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heidi N Leblanc. Retrieved from https://idiyas.com/inventor/heidi-n-leblanc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 12)

% Patents Active = 86.4

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 7.9

ph-index = 9

Forward Citations = 224(Granted Patents)

Company Filing History:

13 out of 1,624

E. R. Squibb Sons, Inc.

Bristol-Myers Squibb Compnay

Oxford Biotherapeutics Ltd

patents

where one patent can have more than one assignee

Years Active: 2011-2022

Loading Chart...

Areas of Expertise:

Human Antibodies

Lymphocyte Activation Gene-3

OX40 Receptor

CD22

BTLA

Glypican-3

Monoclonal Antibodies

CADM1

Binding Molecules

Immunotherapy

Cancer Treatment

Therapeutic Antibodies

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11530267 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-12-20),

2. 11512130 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-11-29),

3. 11236165 - Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof (2022-02-01),

4. 11236164 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-02-01),

5. 11236163 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2022-02-01),

6. 11001630 - Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof (2021-05-11),

7. 10988536 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2021-04-27),

8. 10988535 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2021-04-27),

9. 10344089 - Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof (2019-07-09),

10. 10196452 - Binding molecules to the human OX40 receptor (2019-02-05),

11. 10155813 - Fully human antibodies to BTLA (2018-12-18),

12. 9840562 - Binding molecules to the human OX40 receptor (2017-12-12),

13. 9499632 - Human antibodies that bind CD22 and uses thereof (2016-11-22),

14. 9346882 - Fully human antibodies to BTLA (2016-05-24),

15. 9217033 - Monoclonal antibodies against Glypican-3 (2015-12-22),

Title: **Heidi N Leblanc: Innovator in Monoclonal Antibody Research**

Introduction

Heidi N Leblanc is a notable inventor based in Mountain View, CA, who has made significant contributions to the field of biomedical research. With a remarkable portfolio that includes 22 patents, she is recognized for her pioneering work in the development of human monoclonal antibodies, particularly those targeting the lymphocyte activation gene-3 (LAG-3).

Latest Patents

Among her latest inventions, Heidi has developed isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity. These anti-LAG-3 antibodies hold promise for enhancing immune responses by inhibiting the binding of LAG-3 to MHC Class II molecules, which may lead to the stimulation of antigen-specific T cell responses. Her patents detail the production of nucleic acid molecules encoding these antibodies, along with expression vectors, host cells, and methods for their expression. Furthermore, she has explored immunoconjugates, bispecific molecules, and pharmaceutical compositions that incorporate these innovative antibodies. The scope of her work also encompasses methods for detecting LAG-3 and strategies for stimulating immune responses through combination therapy with additional immunostimulatory antibodies.

Career Highlights

Heidi N Leblanc has worked with prominent organizations in the pharmaceutical and biotech industries, including E.R. Squibb & Sons, L.L.C. and Pfizer Corporation. Her extensive experience in these reputable companies has allowed her to contribute to groundbreaking research and development in antibody therapies.

Collaborations

Throughout her career, Heidi has collaborated with esteemed colleagues such as Mark Yamanaka and Kent B Thudium. These partnerships have played a critical role in advancing her research and expanding the application of her inventions within the scientific community.

Conclusion

Heidi N Leblanc's innovative work in the field of monoclonal antibodies, especially in targeting LAG-3, emphasizes her status as a leading inventor in biomedical research. With an impressive number of patents and valuable collaborations, she continues to shape the future of immunotherapy, offering hope for more effective treatments.

Profile summary based on public USPTO records.